SCHEMBL8510262

SCHEMBL8510262

CC(C)(O)C(=O)N1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 5/20 0.66
CASP6 P55212 1/20 0.66
MAPT P10636 11/20 0.51
ALDH1A1 P00352 8/20 0.51
GAA P10253 5/20 0.51
KDM4E B2RXH2 3/20 0.51
KMT2A Q03164 3/20 0.51
ADRA2C P18825 1/20 0.51
PTK2B Q14289 1/20 0.51
ESR2 Q92731 1/20 0.51
LMNA P02545 7/20 0.50
ALOX12 P18054 4/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
RAD52 P43351 1/20 0.47
MAPK1 P28482 3/20 0.47
HTT P42858 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
FASN P49327 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188121 0.89 GFER (0.68) GFERCASP6MAPTALDH1A1GAA
SCHEMBL25839423 0.86 PANK3 (0.54) GFERCASP6MAPTALDH1A1GAA
SCHEMBL23544885 0.85 AKR1C3 (0.58) GFERCASP6MAPTALDH1A1GAA
SCHEMBL2450111 0.82 GFER (0.63) GFERCASP6MAPTALDH1A1GAA
SCHEMBL188776 0.81 FASN (0.46) GFERCASP6MAPTALDH1A1GAA
SCHEMBL6152043 0.80 GFER (1.00) GFERCASP6MAPTALDH1A1GAA
SCHEMBL6152986 0.80 GFER (1.00) GFERCASP6MAPTALDH1A1GAA
SCHEMBL188503 0.80 GFER (1.00) GFERCASP6MAPTALDH1A1GAA
SCHEMBL28806386 0.79 GFER (0.73) GFERCASP6MAPTALDH1A1GAA
SCHEMBL189134 0.79 GFER (0.68) GFERCASP6MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
EP-2748166-B1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF ASANA BIOSCIENCES LLC (US) 2018-07-11 EP disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GFER 3828/4885CASP6 3379/4885MAPT 470/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK GFER 4102/4885CASP6 3453/4885MAPT 501/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GFER 3828/4885CASP6 3379/4885MAPT 470/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK GFER 1162/4885CASP6 1437/4885MAPT 4723/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GFER 3792/4885CASP6 3264/4885MAPT 438/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GFER 3792/4885CASP6 3264/4885MAPT 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.